Treatment Trials

4 Clinical Trials for Various Conditions

Focus your search

      ACTIVE_NOT_RECRUITING
      An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
      Description

      This study is designed as a long-term extension to Study APL2-C3G-310, and is being conducted to establish the long-term safety and efficacy of pegcetacoplan in patients with C3 glomerulopathy (C3G) or immune-complex membranoproliferative glomerulonephritis (IC-MPGN).

      Conditions
      C3GIC-MPGNC3 GlomerulopathyC3 GlomerulonephritisComplement 3 GlomerulopathyComplement 3 Glomerulopathy (C3G)Complement 3 GlomerulonephritisDense Deposit DiseaseDDDMembranoproliferative GlomerulonephritisMembranoproliferative Glomerulonephritis (MPGN)Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
      Talk to us
      COMPLETED
      Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
      Description

      This is a Phase 3 study to assess the efficacy and safety of twice-weekly subcutaneous (SC) doses of pegcetacoplan compared to placebo in patients with C3 glomerulopathy (C3G) or immune-complex membranoproliferative glomerulonephritis (IC-MPGN) on the basis of a reduction in proteinuria.

      Conditions
      C3GIC-MPGNC3 GlomerulopathyC3 GlomerulonephritisComplement 3 GlomerulopathyComplement 3 Glomerulopathy (C3G)Complement 3 GlomerulonephritisDense Deposit DiseaseDDDMembranoproliferative GlomerulonephritisMembranoproliferative Glomerulonephritis (MPGN)Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
      Talk to us
      ACTIVE_NOT_RECRUITING
      Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN
      Description

      This is a Phase 2, multicenter, open-label, randomized, controlled study designed to evaluate the safety and efficacy of pegcetacoplan in patients who have post-transplant recurrence of C3G or IC-MPGN.

      Conditions
      C3GIC-MPGNRenal TransplantComplement 3 GlomerulopathyComplement 3 Glomerulopathy (C3G)Dense Deposit Disease (DDD)Membranoproliferative GlomerulonephritisMembranoproliferative Glomerulonephritis (MPGN)Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)C3 GlomerulopathyC3 GlomerulonephritisComplement 3 Glomerulonephritis
      Talk to us
      WITHDRAWN
      A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G
      Description

      A Phase 2 Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Clinical Activity of ADX-097 Administered Subcutaneously in Male and Female Participants Aged 18 Years or Older With Immunoglobulin A Nephropathy (IgAN), Lupus Nephritis (LN), or Complement Component 3 Glomerulopathy (C3G)

      Conditions
      IgA NephropathyLupus Nephritis (LN)C3 (Complement Component 3) Glomerulopathy
      Talk to us